The fall COVID-19 vaccine season is starting slowly for Pfizer, with U.S. sales of its Comirnaty shots sinking 25% after federal regulators narrowed recommendations on who should get them.

Drugmaker Pfizer has agreed to lower drug costs under a deal struck with President Donald Trump's administration.

Pfizer surprised Wall Street on Tuesday by predicting bigger-than-expected sales drops this year for two key products: its COVID-19 vaccine and treatment.

COVID-19 vaccine maker Moderna is suing its main competitors Pfizer and the German drugmaker BioNTech.

It’s a move that has been highly anticipated by pediatricians and many parents as coronavirus cases have risen in that age group.

Pfizer and BioNTech have officially submitted a request to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization of their COVID-19 vaccine for children aged 5 to 11.

Pfizer Inc.and BioNTech announced Tuesday they have submitted data to the U.S. Food and Drug Administration (FDA) from the Phase 2/3 trial of their COVID-19 vaccine in children 5 to 12 years of age.

Pfizer plans to request Emergency Use Authorization from the FDA for this age group to receive the vaccine in the coming weeks.

Since the coronavirus pandemic began, Dr. Frank McGeorge has been keeping viewers up-to-date and informed on all fronts.

The CDC’s vaccine advisory panel held a public meeting on Monday and discussed the recent full FDA approval of Comirnaty, Pfizer’s COVID vaccine.

On Monday, the U.S. Food and Drug Administration gave full approval to the Pfizer-BioNTech COVID-19 Vaccine, which will now be marketed as Comirnaty.